Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States

INTRODUCTION: nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited. METHODS: This retrospective cohort study compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sunnie, Signorovitch, James E., Yang, Hongbo, Patterson-Lomba, Oscar, Xiang, Cheryl Q., Ung, Brian, Parisi, Monika, Marshall, John L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182639/
https://www.ncbi.nlm.nih.gov/pubmed/30209750
http://dx.doi.org/10.1007/s12325-018-0784-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182639/
https://www.ncbi.nlm.nih.gov/pubmed/30209750
http://dx.doi.org/10.1007/s12325-018-0784-z

Ejemplares similares